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The management of lupus nephritis (LN) and concomitant thrombotic 
microangiopathy (TMA), with or without antiphospholipid antibodies (aPL), 
remains controversial and few studies are available to inform clinical 
management [1–4] 
The purpose of this multicenter retrospective study was to analyze the impact of 
anticoagulation [vitamin-K-antagonists (VKA)  and/or heparins] in addition to 
conventional immunosuppression on kidney outcomes (assessed at 12 months, 
according to KDIGO guidelines[5]) in patients with biopsy-proven LN and 
concomitant TMA.  
Data source, population, and statistical analysis are detailed in the supplementary 
material. Anticoagulation was considered if given for at least 3 consecutive 
months after TMA diagnosis.  
We retrospectively identified 97 patients with biopsy-proven LN and TMA (2007-
2017). See online supplementary Table S1 for clinical and demographic 
characteristics. Laboratory parameters were collected at the time of the biopsy. 
The mean age of patients was 38.9 ±15.2 years (13–69) and 85 female (87.6%). 
Most had proliferative LN (Class IV in 84.5%). Forty-two(43%) patients presented 
with acute and 55 (57%) with features of chronic TMA. All patients had received 
treatment with standard immunosuppressants (55% mycophenolate, 39% 
cyclophosphamide, 6% other regimen) and steroids. At 12 months, complete 
response (CR) was observed in 37 patients (38.1%), partial response (PR) in 22 
(22.6%) and no response in 38 (39.1%). Sixty-one patients (62.9%) were aPL 
positive and 37 (38.1%) of these patients received anticoagulation with a VKA 
and/or heparins. Mean duration of anticoagulation therapy after TMA and LN 
diagnosis was 7.7 months (3-12).  
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We observed a higher rate of clinical response (CR/PR, together or computed 
separately) in patients who received anticoagulation [CR in 22 (59.46%), PR in 7 
(18.91%); NR in 8 (21.62%)] when compared to those without [CR in 15 (25.0%), 
PR in 15 (25.0%); NR in 30( 50%)], p<0.01) (Table1). 
When limiting the analysis on the 61 patients with aPL, we observed a higher rate 
of complete response in those receiving anticoagulation [patients receiving 
anticoagulant therapy: CR in 22 (59.46%), PR in 7 (18.91%); NR in 8 (21.62%) Vs. 
patients non receiving VKA/heparins: CR in 8 (30.77%), PR in 7 (26.92%); NR in 
8 (34.62%),p=0.046](Figure 1). 
After multivariate analysis, aPL positivity (any) (β=1.23,OR, 2.4;95% confidence 
interval-CI-, 1.2–7.3;p=0.03), anti-dsDNA positivity (β=1.98,OR,12.8; 95% CI 3.0-
71.3; p=0.002), and chronic features of TMA (β=1.31,OR 3.0; 95%CI 1.2–17.5; p 
=0.04) were all associated with no kidney response. 
When limiting the analysis to aPL positive patients, after adjusting for type of 
immunosuppressant therapy and LN class, variables that were significantly 
associated with CR+PR were features of acute TMA rather than chronic (β=1.95, 
OR, 8.62; 95% CI 1.4–97.1; p = 0.03) and the use of VKA/heparins (β=1.21OR, 2.1; 
95% CI, 1.02–16.2; P = 0.046).   
In summary, in our study the use of anticoagulation was associated with any 
response to treatment at 1 year, in line with the fact that about 60% of the patients 
with CR received VKA or heparins. Similarly, when limiting the analysis to patients 
with aPL, we observed a rate of any response (either CR+PR) as high as 66% in 
patients receiving anti-coagulant treatment when compared to those receiving 
immunosuppression alone (34%).  
 5 
Despite its limitations (the relatively short duration of follow-up to gauge the 
relapse rate; lack of standardized protocol for LN treatment; the use of 
anticoagulation agents was not randomized but based on the treating physicians’ 
judgment), this study represents the largest available multicentre cohort of real-
life SLE patients with biopsy proven LN and concomitant TMA.  
To conclude, in patients with concomitant LN and TMA, the use of anticoagulation 
appeared protective and warrants further investigation as a therapeutic tool; the 
presence of aPL, anti-dsDNA antibodies and chronic features of TMA were 
associated with poorer kidney outcomes.  
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Figure 1  
Comparison of kidney outcomes between patients receiving anticoagulation and 
those without (Panel A, all 97 patients; Panel B, limiting to patients positive for 
antiphospholipid antibodies) 
Table 1. Univariate analysis of patient characteristicsby kidney outcome  
Table 1S. Baseline clinical characteristics of patients with TMA and LN 
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Table 1S 
Characteristics  Total % 
Female  85 87,6 
Clinical features  
Skin Involvement  32 33,0 
Hematological involvement  35 36,1 
Joint involvement  75 77,3 
NPSLE  2 2,1 
History of hypertension   55 56,7 
APS*  13 13,4 
Thrombotic APS  10 10,3 
Obstetric APS  5 5,2 
Clinical features at the time of biopsy 
Microangiopathic hemolytic anemia   3 3,1 
Thrombocytopenia (<100,000 platelets/μL)   15 15,5 
Laboratory profile  
Anti-Ro positivity   36 37,1 
Anti-La positivity   9 9,3 
aPL antibody positivity  61 62,9 
LAC  37 38,1 
aCL  35 36,1 
anti-Beta2GPI  22 22,7 
Triple Positivity  15 15,5 
Anti-dsDNA  43 44,3 
Creatinine > 3 mg/dL  27 27,8 
low C3 levels   77 79,3 
low C4 levels   27 27,8 
Microscopic hematuria (>5 erythrocytes/HPF)  69 71,1 
Proteinuria > 3.5 mg/d  41 42,3 
Arterial hypertension  63 64,9 
Hyperlipemia  45 46,3 
aGAPPS ≥ 10  29 29,9 
aGAPPS ≥ 12  24 24,7 
Therapy 
ACE inhibitor or ARB use  62 63,9 
Anti-thrombotic therapy    
Aspirin**  54 55,7 
Anticoagulation***  38 39,2 
Vitamin K antagonist  31 32,0 
heparins  7 7,2 
Immunosuppressants (Induction therapy for LN)****    
Mycophenolate mofetil  53 54,6 
Cyclophosphamide   38 39,2 
EUROLUPUS regimen  28 28,9 
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*according to Sydney criteria (Miyakis et al., 2006); **in 47 patients treatment was initiated before 
LN diagnosis;  *** 10 patients on VKA before LN diagnosis; **** patients received different steroids 
regimens in association to immunosuppressant agents. The majority of them receive bolus doses of 
methyl-prednisone followed by 0.8/kg/day of oral prednisone tapered to low-dose (e.g. < 7.5 mg/dl) 
within 6 months from induction. NPSLE, neuropsychiatric SLE; Miyakis, S., Lockshin, M. D., Atsumi, T., 
Branch, D. W., Brey, R. L., Cervera, R., … Krilis, S. A. (2006). International consensus statement on an 
update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of 
Thrombosis and Haemostasis : JTH, 4(2), 295–306. 
Other  6 6,2 
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Table 1 
 
Characteristics 
  
Total % Any 
response 
% CR % %CR PR % %PR NR % %NR p p* 
Female 85 87,6 52 53,6 30 30,9 81,1 22 22,68041 100 33 34,02 86,84 0,2924 0,85 
Clinical features                            
APS* 13 13,4 10 10,3 5 5,2 13,5 5 5,2 22,7 3 3,1 7,9 0,2629 0,22 
aPL antibody positivity 61 62,9 26 26,8 15 15,5 40,5 11 11,3 50,0 35 36,1 92,1 <0.001 <0.001 
LAC 37 38,1 17 17,5 7 7,2 18,9 10 10,3 45,5 20 20,6 52,6 0,0079 0,018 
aCL 35 36,1 20 20,6 8 8,2 21,6 12 12,4 54,5 15 15,5 39,5 0,0334 0,57 
anti-Beta2GPI 22 22,7 12 12,4 7 7,2 18,9 5 5,2 22,7 10 10,3 26,3 0,7464 0,49 
Triple Positivity 15 15,5 8 8,2 5 5,2 13,5 3 3,1 13,6 7 7,2 18,4 0,811 0,51 
Anti-dsDNA 43 44,3 22 22,7 13 13,4 35,1 9 9,3 40,9 24 24,7 63,2 0,041 0,0214 
Low C3 levels  77 79,3 36 37,1 25 25,8 67,6 11 11,3 50,0 38 39,2 100,0 0,001 <0.001 
Low C4 levels  27 27,8 15 15,5 8 8,2 21,6 7 7,2 31,8 12 12,4 31,6 0,5627 0,64 
Arterial hypertension 
  63 64,9 36 37,1 23 23,7 62,2 13 13,4 59,1 28 28,9 73,7 0,4252 0,27 
Hyperlipemia 
  45 46,3 27 27,8 17 17,5 45,9 10 10,3 45,5 18 18,6 47,4 0,98 1 
aGAPPS ≥ 12 
  24 24,7 10 10,3 6 6,2 16,2 4 4,1 18,2 14 14,4 36,8 0,0846 0,0267 
LN class IV 82 84,5 50 51,5 32 33,0 86,5 18 18,6 81,8 32 33,0 84,2 0,8891 1 
Therapy                               
Mycophenolate mofetil 53 54,6 32 33,0 21 21,6 56,8 11 11,3 50,0 21 21,6 55,3 0,8764 1 
Cyclophosphamide  38 39,2 22 22,7 14 14,4 37,8 8 8,2 36,4 16 16,5 42,1 0,888 0,67 
EUROLUPUS regimen 28 28,9 16 16,5 11 11,3 29,7 5 5,2 22,7 12 12,4 31,6 0,7583 0,65 
Other 
immunosuppresants 6 6,2 4 4,1 2 2,1 5,4 2 2,1 9,1 2 2,1 5,3 0,8128 1 
Anticoagulation 37 38,1 29 29,9 22 22,7 59,5 7 7,2 31,8 8 8,2 21,1 0,0022 0,0059 
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*computing together any response, CR+PR. CR, complete response; PR, partial response; NR, no response; aGAPPS, adjusted global 
antiphospholipid score.  
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